Growth Metrics

Merck (MRK) Short-term Investments (2016 - 2026)

Merck has reported Short-term Investments over the past 17 years, most recently at $375.0 million for Q1 2026.

  • Quarterly Short-term Investments fell 37.4% to $375.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $375.0 million through Mar 2026, down 37.4% year-over-year, with the annual reading at $447.0 million for FY2024, 77.38% up from the prior year.
  • Short-term Investments was $375.0 million for Q1 2026 at Merck, up from $45.0 million in the prior quarter.
  • Over five years, Short-term Investments peaked at $718.0 million in Q2 2023 and troughed at $40.0 million in Q1 2024.
  • The 5-year median for Short-term Investments is $375.0 million (2026), against an average of $361.0 million.
  • Year-over-year, Short-term Investments tumbled 94.12% in 2024 and then surged 1397.5% in 2025.
  • A 5-year view of Short-term Investments shows it stood at $498.0 million in 2022, then crashed by 49.4% to $252.0 million in 2023, then skyrocketed by 77.38% to $447.0 million in 2024, then plummeted by 89.93% to $45.0 million in 2025, then soared by 733.33% to $375.0 million in 2026.
  • Per Business Quant, the three most recent readings for MRK's Short-term Investments are $375.0 million (Q1 2026), $45.0 million (Q3 2025), and $615.0 million (Q2 2025).